Yıl: 2022 Cilt: 62 Sayı: 3 Sayfa Aralığı: 307 - 314 Metin Dili: İngilizce DOI: 10.14744/hnhj.2022.16779 İndeks Tarihi: 30-09-2022

Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus

Öz:
Introduction: The aim of the present study was to investigate serum phosphate and uric acid levels (UA) in juvenile sys- temic lupus erythematosus (jSLE) and to ascertain their relationship, if any, with disease activity and lupus nephritis. Methods: Included in the study were 18 children with jSLE who were investigated retrospectively during the active phase (AP) and remission phase (RP) of jSLE. Results: Serum phosphate and UA levels were found to be significantly lower in AP than in the RP (2.5±0.3/4.2±0.08 mg/dL, p=0.0001 and 2.9±0.3/5±0.2 mg/dL, p=0.0001, respectively). Serum phosphate levels were strongly correlated with serum albumin levels (r=0.772, p=0.0001) and platelet count (r=0.735, p=0.001) and negative associated with D-dimer (r=−0.750, p=0.0001) in AP. No correlation was identified between serum phosphate and UA or creatinine levels in patients with AP, while serum phosphate and UA levels were similar in children with and without nephritis (p>0.05). Serum phosphate lev- els were correlated with platelet count and UA levels and were inversely related with D-dimer levels in jSLE patients with nephritis (p<0.05). Discussion and Conclusion: Serum phosphate and UA levels can reflect the activation and low serum levels may be useful biomarkers for the detection of AP in jSLE patients with and without nephritis.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Gottschalk TA, Tsantikos E, Hibbs ML. Pathogenic inflamma- tion and its therapeutic targeting in systemic lupus erythe- matosus. Front Immunol 2015;6:550.
  • 2. Hesselink DA, Aarden LA, Swaak AJ. Profiles of the acute-phase reactants C-reactive protein and ferritin related to the disease course of patients with systemic lupus erythematosus. Scand J Rheumatol 2003;32:151–5.
  • 3. Abdel Galil SM, Edrees AM, Ajeeb AK, Aldoobi GS, El-Boshy M, Hussain W. Prognostic significance of platelet count in SLE pa- tients. Platelets 2017;28:203–7.
  • 4. Gordon C, Emery P. Cytokines and the acute phase response in SLE. Lupus 1993;2:345–7.
  • 5. Isenberg DA, Allen E, Farewell V, D'Cruz D, Alarcón GS, Ara- now C, Bruce IN, et al. An assessment of disease flare in pa- tients with systemic lupus erythematosus: A comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis 2011;70:54–9.
  • 6. Ghaemi-Oskouie F, Shi Y. The role of uric acid as an endoge- nous danger signal in immunity and inflammation. Curr Rheumatol Rep 2011;13:160–6.
  • 7. Hooper DC, Spitsin S, Kean RB, Champion JM, Dickson GM, Chaudhry I, et al. Uric acid, a natural scavenger of peroxyni- trite, in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A 1998;95:675–80.
  • 8. Morato-Conceicao YT, Alves-Junior ER, Arruda TA, Lopes JC, Fontes CJ. Serum uric acid levels during leprosy reaction episodes. PeerJ 2016;4:e1799.
  • 9. Bairaktari ET, Kakafika AI, Pritsivelis N, Hatzidimou KG, Tsianos EV, Seferiadis KI, et al. Hypouricemia in individuals admit- ted to an inpatient hospital-based facility. Am J Kidney Dis 2003;41:1225–32.
  • 10. Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth fac- tor 23 and Klotho: Physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol 2013;75:50333.
  • 11. Gaasbeek A, Meinders AE. Hypophosphatemia: An update on its etiology and treatment. Am J Med 2005;118:1094–101.
  • 12. Knochel JP. The pathophysiology and clinical characteristics of severe hypophosphatemia. Arch Intern Med 1977;137:203– 20.
  • 13. da Cunha DF, dos Santos VM, Monterio JP, de Carvalho da Cunha SF. Hypophosphatemia in acute-phase response syn- drome patients. Preliminary data. Miner Electrolyte Metab 1998;24:337–40.
  • 14. Smith EL, Shmerling RH. The American College of rheuma- tology criteria for the classification of systemic lupus erythe- matosus: Strengths, weaknesses, and opportunities for im- provement. Lupus 1999;8:586–95.
  • 15. Lam GK, Petri M. Assessment of systemic lupus erythemato- sus. Clin Exp Rheumatol 2005;23(Suppl 39):S120–32.
  • 16. Amanzadeh J, Reilly RF Jr. Hypophosphatemia: An evidence- based approach to its clinical consequences and manage- ment. Nat Clin Pract Nephrol 2006;2:136–48.
  • 17. Martín NE, Nieto VG. Hypouricemia and tubular transport of uric acid. Nefrologie 2011;31:44–50.
  • 18. Ikeda S, Yamamoto H, Masuda M, Takei Y, Nakahashi O, Kozai M, et al. Downregulation of renal type IIa sodium-depen- dent phosphate cotransporter during lipopolysaccharide- induced acute inflammation. Am J Physiol Renal Physiol 2014;306:F744–50.
  • 19. Barak V, Schwartz A, Kalickman I, Nisman B, Gurman G, Shoen- feld Y. Prevalence of hypophosphatemia in sepsis and infec- tion: The role of cytokines. Am J Med 1998;104:40–7.
  • 20. Yang J, Yang X, Zou H, Li M. Oxidative stress and treg and Th17 dysfunction in systemic lupus erythematosus. Oxid Med Cell Longev 2016;2016:2526174.
  • 21. Li Y, Gorelik G, Strickland FM, Richardson BC. Oxidative stress, T cell DNA methylation, and lupus. Arthritis Rheumatol 2014;66:1574–82.
  • 22. Giovannini I, Chiarla C, Giuliante F, Vellone M, Ardito F, Pallavicini F, et al. Biochemical and clinical correlates of hy- pouricemia in surgical and critically ill patients. Clin Chem Lab Med 2007;45:1207–10.
  • 23. Yung S, Chan TM. Mechanisms of kidney injury in lupus nephritis - the role of anti-dsDNA antibodies. Front Immunol 2015;6:475.
  • 24. Yung S, Cheung KF, Zhang Q, Chan TM. Anti-dsDNA antibod- ies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol 2010;21:1912–27.
  • 25. Levy DM, Kamphuis S. Systemic lupus erythematosus in chil- dren and adolescents. Pediatr Clin North Am 2012;59:345–64.
  • 26. Dhingra S, Qureshi R, Abdellatif A, Gaber LW, Truong LD. Tubulointerstitial nephritis in systemic lupus erythematosus: Innocent bystander or ominous presage. Histol Histopathol 2014;29:553–65.
  • 27. Fujiwara I, Ogawa E, Kondo Y, Ohura T, Iinuma K. Hypophos- phatemia in juvenile patients with systemic lupus erythe- matosus. Pediatr Int 2003;45:23–30.
APA Sav N, CETIN N, BİLAL Y (2022). Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus. , 307 - 314. 10.14744/hnhj.2022.16779
Chicago Sav Nadide Melike,CETIN NURAN,BİLAL YILDIZ Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus. (2022): 307 - 314. 10.14744/hnhj.2022.16779
MLA Sav Nadide Melike,CETIN NURAN,BİLAL YILDIZ Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus. , 2022, ss.307 - 314. 10.14744/hnhj.2022.16779
AMA Sav N,CETIN N,BİLAL Y Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus. . 2022; 307 - 314. 10.14744/hnhj.2022.16779
Vancouver Sav N,CETIN N,BİLAL Y Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus. . 2022; 307 - 314. 10.14744/hnhj.2022.16779
IEEE Sav N,CETIN N,BİLAL Y "Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus." , ss.307 - 314, 2022. 10.14744/hnhj.2022.16779
ISNAD Sav, Nadide Melike vd. "Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus". (2022), 307-314. https://doi.org/10.14744/hnhj.2022.16779
APA Sav N, CETIN N, BİLAL Y (2022). Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus. Haydarpaşa Numune Medical Journal, 62(3), 307 - 314. 10.14744/hnhj.2022.16779
Chicago Sav Nadide Melike,CETIN NURAN,BİLAL YILDIZ Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus. Haydarpaşa Numune Medical Journal 62, no.3 (2022): 307 - 314. 10.14744/hnhj.2022.16779
MLA Sav Nadide Melike,CETIN NURAN,BİLAL YILDIZ Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus. Haydarpaşa Numune Medical Journal, vol.62, no.3, 2022, ss.307 - 314. 10.14744/hnhj.2022.16779
AMA Sav N,CETIN N,BİLAL Y Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus. Haydarpaşa Numune Medical Journal. 2022; 62(3): 307 - 314. 10.14744/hnhj.2022.16779
Vancouver Sav N,CETIN N,BİLAL Y Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus. Haydarpaşa Numune Medical Journal. 2022; 62(3): 307 - 314. 10.14744/hnhj.2022.16779
IEEE Sav N,CETIN N,BİLAL Y "Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus." Haydarpaşa Numune Medical Journal, 62, ss.307 - 314, 2022. 10.14744/hnhj.2022.16779
ISNAD Sav, Nadide Melike vd. "Decreased Uric Acid and Phosphorus Levels in Active Juvenile Systemic Lupus Erythematosus". Haydarpaşa Numune Medical Journal 62/3 (2022), 307-314. https://doi.org/10.14744/hnhj.2022.16779